BIO in the news: Drug, biotech industries weigh election's impact

11/3/2004 | USA Today · MarketWatch · Kentucky.com

The outcome of the presidential election sent pharmaceutical and biotechnology stocks rising, but at least one analyst said the "enthusiasm could be short-lived" because the issues that faced the industries before the election still remain. But others see President George W. Bush's re-election as making it less likely the government will impose price controls. Scientists anticipate conflict between individual states and the federal government over a variety of issues during Bush's second term. Carl Feldbaum, president of the Biotechnology Industry Organization, argues "the big issues for biotech are who the new president will appoint to key positions such as the FDA commissioner and other agencies if vacancies occur."

View Full Article in:

USA Today · MarketWatch · Kentucky.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI